James Yi Li


Thank you for your interest. Before you communicate with one of our attorneys, please note: Any comments our attorneys share with you are general information and not legal advice. No attorney-client relationship will exist between you or your business and O’Melveny or any of its attorneys unless conflicts have been cleared, our management has given its approval, and an engagement letter has been signed. Meanwhile, you agree: we have no duty to advise you or provide you with legal assistance; you will not divulge any confidences or send any confidential or sensitive information to our attorneys (we are not in a position to keep it confidential and might be required to convey it to our clients); and, you may not use this contact to attempt to disqualify O’Melveny from representing other clients adverse to you or your business. By clicking "accept" you acknowledge receipt and agree to all of the terms of this paragraph and our Disclaimer.


James Yi Li is a litigation counsel in the firm's New York office. His practice focuses on life sciences patent litigation and contested matters involving chemistry, pharmaceuticals, and biotechnology. James has significant experience litigating under the Hatch-Waxman Act and the Biologics Price Competition and Innovation Act, and has played management roles in fact and expert discovery and pre-trial strategy for several cases. James has also defended compound and formulation patents through two completed trials.

James received his law degree from Harvard Law School, cum laude, in 2015, where he served as the Submissions Editor for the Harvard Journal of Law & Technology and a Senior Editor for the Harvard Negotiation Law Review. He graduated with a B.S.E. in Biomedical Engineering from the University of Michigan, summa cum laude, in April 2011. He obtained his Master of Engineering in Pharmaceutical Engineering from the University of Michigan in December 2011.


Bar Admissions

  • New York

Registered to Practice

  • US Patent & Trademark Office


  • Harvard Law School, J.D., cum laude
  • University of Michigan, M.Eng., Pharmaceutical Engineering
  • University of Michigan, B.S.E., Biomedical Engineering, summa cum laude

Professional Activities


  • Co-Author, “AI and Life Sciences Patents: Separating Myth From Reality,” New York Law Journal (March 20, 2020)
  • Co-Author (Yu J, Yu J, Mani RS, et al.), “An Integrated Network of Androgen Receptor, Polycomb, and TMPRSS2-ERG Gene Fusions in Prostate Cancer Progression,” Cancer Cell. 2010, 17(5):443-454.


  • “Paragraph IV Patent Protection and Litigation: Addressing the Complex Challenges,” The Knowledge Group (October 3, 2019)